Provectus Biopharmaceuticals, Inc. (PVCT)
OTCMKTS · Delayed Price · Currency is USD
0.0670
-0.0018 (-2.62%)
At close: Jul 7, 2026
Provectus Biopharmaceuticals Employees
Provectus Biopharmaceuticals had 6 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$9,580
Profits / Employee
-$930,200
Market Cap
28.92M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 6 | 0 | - |
| Dec 31, 2024 | 6 | 2 | 50.00% |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | 0 | - |
| Dec 31, 2021 | 4 | 2 | 100.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Oncotelic Therapeutics | 43 |
| Nuo Therapeutics | 10 |
| ZIVO Bioscience | 7 |
| Anebulo Pharmaceuticals | 3 |
| Vicapsys Life Sciences | 2 |
Provectus Biopharmaceuticals News
- 18 hours ago - Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose - GlobeNewsWire
- 7 days ago - Provectus awarded patent for light-independent antibacterial eye drop - TheFly
- 7 days ago - Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections - GlobeNewsWire
- 12 days ago - Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium) - GlobeNewsWire
- 4 weeks ago - Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders - GlobeNewsWire
- 7 weeks ago - Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End - GlobeNewsWire
- 2 months ago - Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus's VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis - GlobeNewsWire
- 2 months ago - Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee - GlobeNewsWire